Coegin Pharma (NGM:COEGIN) EBIT: kr-19.58 Mil (TTM As of Mar. 2026)


NGM:COEGIN Coegin Pharma NGM:COEGIN
29 GF Score
Price kr3.62
! 2 Warning Signs
View Full Analysis

What is Coegin Pharma EBIT?

Coegin Pharma NGM:COEGIN +3.72% 29 EBIT is kr-19.58 Mil as of Mar. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Coegin Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-4.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-19.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Coegin Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was -249.64%. Coegin Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12,469.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Coegin Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -22.26%.

Coegin Pharma  (NGM:COEGIN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Coegin Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-19.016 * ( 1 - 0% )/( (11.277 + 3.958)/ 2 )
=-19.016/7.6175
=-249.64 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13.343 - 0.669 - ( 7.923 - max(0, 8.599 - 9.996+7.923))
=11.277

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.209 - 0.988 - ( 9.266 - max(0, 2.237 - 11.5+9.266))
=3.958

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Coegin Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-19.016/( ( (0.113 + max(-7.185, 0)) + (0.192 + max(-0.611, 0)) )/ 2 )
=-19.016/( ( 0.113 + 0.192 )/ 2 )
=-19.016/0.1525
=-12,469.51 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.073 + 0 + 1.341) - (0.669 + 0 + 7.93)
=-7.185

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.074 + 0 + 1.552) - (0.988 + 0 + 1.249)
=-0.611

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Coegin Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-19.576/87.945
=-22.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma EBIT Related Terms

Coegin Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Coegin Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma EBIT Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -27.15 -35.02 -27.93 -23.33 -20.47

Coegin Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.63 -3.91 -4.06 -6.86 -4.75

NGM:COEGIN vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Coegin Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coegin Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's EV-to-EBIT falls into.


NGM:COEGIN
29GF Score
Coegin Pharma NGM:COEGIN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-19.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-19.58 Mil mean?
Coegin Pharma (NGM:COEGIN) has a EBIT of kr-19.58 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Coegin Pharma.
Is Coegin Pharma's EBIT too high?
Coegin Pharma's current EBIT is kr-19.58 Mil. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's EBIT compare to VRTX and REGN?
Coegin Pharma's EBIT of kr-19.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Coegin Pharma. Coegin Pharma's current EBIT is kr-19.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current EBIT of kr-19.58 Mil. The current EBIT is kr-19.58 Mil. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current EBIT is kr-19.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score

Get the complete analysis for NGM:COEGIN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.62
Price